Skip to main content
Print Save

Taxol Disease Interactions

There are 6 disease interactions with Taxol (paclitaxel).

Major

Antineoplastics (applies to Taxol) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  2. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories (2002):
  3. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb (2001):
  4. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb (2001):
  5. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation (2001):
  6. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb (2001):
  7. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb (2001):
  8. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) (2001):
  9. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  10. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  11. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  12. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  13. "Product Information. Fludara (fludarabine)." Berlex Laboratories (2001):
  14. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn (2001):
  15. "Product Information. Matulane (procarbazine)." Roche Laboratories (2001):
  16. "Product Information. DTIC-Dome (dacarbazine)." Bayer (2001):
  17. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn (2001):
  18. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc (2001):
  19. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company (2001):
  20. "Product Information. Hycamtin (topotecan)." SmithKline Beecham (2001):
  21. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer (2001):
  22. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  23. "Product Information. Nipent (pentostatin)." Hospira Inc (2001):
  24. "Product Information. Tabloid (thioguanine)." Prasco Laboratories (2001):
  25. "Product Information. Xeloda (capecitabine)." Roche Laboratories (2001):
  26. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  27. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome (2001):
  28. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  29. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc (2001):
  30. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn (2001):
  31. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation (2001):
  32. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  33. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  34. "Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc (2014):
  35. "Product Information. Blincyto (blinatumomab)." Amgen USA (2014):
  36. "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb (2014):
  37. "Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation (2015):
  38. "Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb (2015):
  39. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 39 references
Major

Paclitaxel (applies to Taxol) conduction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

Severe conduction abnormalities, some requiring pacemaker placement, have been reported during paclitaxel therapy. Therapy with paclitaxel should be administered cautiously in patients with or predisposed to conduction disorders. Clinical monitoring of cardiac function is recommended during subsequent paclitaxel therapy.

References

  1. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC "Clinical toxicities encountered with paclitaxel (Taxol)." Semin Oncol 20(4 Suppl) (1993): 1-15
  2. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  3. "Product Information. Abraxane (PACLitaxel protein-bound)." American Pharmaceutical Partners
  4. "Product Information. Paclitaxel (paclitaxel)." Sandoz Pharmaceuticals Corporation (2016):
View all 4 references
Major

Paclitaxel (applies to Taxol) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Paclitaxel is extensively metabolized by the liver. Patients with moderate to severe hepatic impairment may be at increased risk for hepatotoxicity. Additionally, myelotoxicity of paclitaxel may be exacerbated in patients with serum total bilirubin >2 times ULN. Therapy with paclitaxel should be administered cautiously and at a reduced dosage in patients with compromised hepatic function.

References

  1. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  2. "Product Information. Abraxane (PACLitaxel protein-bound)." American Pharmaceutical Partners
  3. "Product Information. Paclitaxel (paclitaxel)." Sandoz Pharmaceuticals Corporation (2016):
Major

Paclitaxel (applies to Taxol) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever, Bleeding

Paclitaxel induces dose-dependent myelosuppression, primarily affecting neutrophils. Anemia characterized as a red blood cell count <11 g/dl has been reported in 78% of patients administered paclitaxel. Thrombocytopenia is uncommon and rarely severe. Therapy with paclitaxel should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld when neutrophil counts fall below 1500/mm3 and/or platelet counts fall below 100,000/mm3. Paclitaxel injection should not be used in patients with solid tumors with baseline neutrophil counts less than 1500/mm3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of less than 1000/mm3. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

References

  1. Reed E, Kohn EC, Sarosy G, Christian M, Goldspiel B, Davis P, Jacob J, Maher M "The incidence of severe side effects from dose intense paclitaxel, administered at one institution (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 36 (1995): a14291995
  2. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC "Clinical toxicities encountered with paclitaxel (Taxol)." Semin Oncol 20(4 Suppl) (1993): 1-15
  3. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  4. "Product Information. Abraxane (PACLitaxel protein-bound)." American Pharmaceutical Partners
  5. "Product Information. Paclitaxel (paclitaxel)." Sandoz Pharmaceuticals Corporation (2016):
View all 5 references
Major

Paclitaxel (applies to Taxol) peripheral neuropathy

Major Potential Hazard, Moderate plausibility.

Dose-dependent peripheral neuropathy has been reported in 60% of patients during paclitaxel therapy. Severe peripheral neuropathy is rare and requires a 20% reduction in dosage of paclitaxel. Therapy with paclitaxel should be administered cautiously in patients with or predisposed to peripheral neuropathy.

References

  1. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC "Clinical toxicities encountered with paclitaxel (Taxol)." Semin Oncol 20(4 Suppl) (1993): 1-15
  2. Liu JM, Chen YM, Chao Y, Liu TW, Chou CM, Chen LT, Yu WL, Whangpeng J "Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region." J Natl Cancer Inst 88 (1996): 1000-2
  3. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  4. "Product Information. Abraxane (PACLitaxel protein-bound)." American Pharmaceutical Partners
  5. "Product Information. Paclitaxel (paclitaxel)." Sandoz Pharmaceuticals Corporation (2016):
View all 5 references
Moderate

Paclitaxel (applies to Taxol) anaphylaxis

Moderate Potential Hazard, Moderate plausibility.

Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in patients receiving paclitaxel. It is recommended that all patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists. Patients who have developed severe hypersensitivity reactions should not be rechallenged with paclitaxel injection.

References

  1. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb (2001):
  2. "Product Information. Abraxane (PACLitaxel protein-bound)." American Pharmaceutical Partners
  3. "Product Information. Paclitaxel (paclitaxel)." Sandoz Pharmaceuticals Corporation (2016):

Taxol drug interactions

There are 413 drug interactions with Taxol (paclitaxel).

Taxol alcohol/food interactions

There is 1 alcohol/food interaction with Taxol (paclitaxel).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer